Replies to post #64640 on SOHM Inc (SHMN)

[hardlesson]

The timing is hard to dissect, as many PR's were only on the old Sohm website, and now they can't be accessed as they've been removed from the new website. Brainwise was technically a little before Aguilar and Rushing were appointed as advisors, might have been a little limited in what they could "say" or contribute...though as you're pointing out they were "advisors." Also as you point out, now they may have more teeth as Officers/Employees/Management/Leadership.

They still seem to be interested in a Brainwise "product" as the most recent quarterly includes an "Omega 3 Oral syrup." (?)

However, whatever happened to Gabapentin? What did Aguilar say about it?

Gabapentin isn't in the Quarterly as a "saleable product." Have they abandoned Gabapentin?





TIA. hL shmn

[Myth]

lol...and what specifically did you expect those advisors to say ?

Aguilar, Dewey & Bhatt

[hardlesson]

Gabapentin vs. Levetiracetam. The differences:

Did Sohm abandon Gabapentin (anticonvulsant, non opioid) for Levetiracetam (antiepileptic, non opioid)?

https://www.goodrx.com/compare/neurontin-vs-keppra

Or do they still plan to offer gabapentin for the nerve "pain"?



https://x.com/sohminc/status/1524071104993579008?s=20

https://my.clevelandclinic.org/health/drugs/21561-gabapentin

Also, why is BiomedWire talking about FDA labeling changes to Opioids, and including SHMN in the discussion?
https://www.biomedwire.com/fda-announces-changes-to-safety-labeling-requirements-for-opioid-medications/
"For companies engaged in manufacturing generic analgesics, such as SOHM Inc. (OTC: SHMN), the new guidelines could help ensure that only those who need those medications can access them."

Analgesics?
https://www.ncbi.nlm.nih.gov/books/NBK560692/#:~:text=Analgesics%20are%20medications%20used%20in,local%20anesthetics%2C%20and%20opioids).

__

hL shmn